# Pharmacodynamic Principles: Concentration-Response Relationships in Therapy


## Key Takeaways

- **Potency vs. Efficacy:** Potency defines the drug concentration required for a given effect (e.g., EC50), influencing dose magnitude, while efficacy represents the maximum achievable effect, determining if a drug can achieve the desired clinical outcome regardless of dose. For instance, morphine and fentanyl are both highly efficacious analgesics, but differ significantly in potency.
- **Antimicrobial Pharmacodynamic Indices:** For beta-lactams, efficacy is primarily driven by the **Time above Minimum Inhibitory Concentration (T>MIC)**, necessitating dosing intervals that maintain drug concentrations above the MIC for a specific percentage of the dosing period (e.g., 60-70% for Enterobacteriaceae). Conversely, aminoglycosides and fluoroquinolones exhibit **concentration-dependent killing**, where the **Peak/MIC ratio** or **AUC/MIC ratio** predicts efficacy, favoring larger, less frequent doses.
- **Therapeutic Index and Species Variability:** The therapeutic index, the ratio of toxic to effective concentrations, guides dosing precision and safety assessment; a narrow index demands careful individualization and monitoring. Species-specific differences in drug metabolism and receptor sensitivity significantly alter the therapeutic index, meaning values derived from one species cannot be directly extrapolated to another.
- **Integration of Pharmacokinetics and Pharmacodynamics:** Achieving pharmacodynamic targets (e.g., T>MIC) is contingent on pharmacokinetic parameters like drug half-life and volume of distribution. A drug with a long half-life might achieve a T>MIC target with once-daily dosing, whereas a short half-life drug may require continuous infusion or more frequent administration.
- **Clinical Application and Monitoring:** Dosing strategies must align with the drug's pharmacodynamic index (time-dependent vs. concentration-dependent killing). For example, beta-lactams require frequent dosing to maintain T>MIC, while aminoglycosides benefit from large, infrequent doses to maximize the Peak/MIC ratio. Monitoring parameters should correspond to the relevant PD index, with trough concentrations for time-dependent drugs and peak concentrations for concentration-dependent drugs.

---

Pharmacodynamics describes the relationship between drug concentration at the site of action and the resulting pharmacologic effect. For the practicing veterinarian, this relationship determines why two drugs in the same class may require different dosing intervals, why a drug may fail despite susceptible pathogen testing, and why toxicity can occur at concentrations that are therapeutic for another patient. This article examines the core pharmacodynamic parameters, their integration with pharmacokinetic data, and their application to clinical dosing decisions across species.

The intended reader is the clinician who seeks a working framework for interpreting drug labels, designing dosing regimens, and troubleshooting therapeutic failure. The focus is on concentration-response relationships, drug potency and efficacy, and the therapeutic index as these concepts apply to antimicrobial, analgesic, and antifungal therapy. Detailed pharmacokinetic modeling is outside the scope, but the points of intersection between pharmacokinetics and pharmacodynamics are addressed where they directly inform dosing strategy.

The central clinical question is straightforward: given a drug, a patient, and a pathogen or target tissue, what concentration profile over time produces the desired effect with acceptable toxicity? Answering this question requires distinguishing between the intrinsic activity of a drug and the exposure needed to realize that activity.

## At a Glance

| Parameter | Definition | Clinical Relevance |
|-----------|-----------|-------------------|
| Potency | Concentration required to produce a given effect (EC50) | Determines dose magnitude, not maximum effect |
| Efficacy | Maximum effect a drug can achieve | Determines whether a drug can produce the desired outcome at any dose |
| Therapeutic index | Ratio of toxic concentration to effective concentration | Guides monitoring and margin-of-safety assessment |
| MIC | Lowest antimicrobial concentration inhibiting visible growth | Reference point for exposure targets in antimicrobial therapy |
| Time above MIC (T>MIC) | Duration of dosing interval that drug concentration exceeds MIC | Primary PD index for beta-lactams |
| Concentration-dependent killing | Bactericidal rate increases with drug concentration | Primary PD index for aminoglycosides and fluoroquinolones |
| Postantibiotic effect | Persistent suppression of bacterial growth after drug removal | Permits extended dosing intervals for certain drug-pathogen pairs |

## Concentration-Response Relationships

The fundamental pharmacodynamic relationship is the concentration-effect curve. As drug concentration at the effect site rises, the magnitude of effect increases along a sigmoidal curve until a plateau is reached. The position of the curve along the concentration axis defines potency. A drug that achieves 50% of its maximum effect at a low concentration is potent, one that requires higher concentrations is less potent. Potency matters for dose selection but does not determine the ceiling of effect.

Efficacy, in contrast, is the maximum effect attainable. A drug with high potency but low efficacy may produce a strong response at low doses yet never achieve the desired clinical outcome. A drug with low potency but high efficacy may require large doses but can produce the full therapeutic effect. For example, morphine and fentanyl differ in potency, but both can produce profound analgesia given sufficient exposure. The distinction becomes clinically critical when comparing drugs within a class for a specific indication.

The shape of the concentration-effect curve also carries information. The Hill coefficient, or slope factor, describes how steeply the effect changes with concentration. A steep curve means small changes in concentration produce large changes in effect, which narrows the margin between subtherapeutic and toxic exposure. A shallow curve permits wider concentration fluctuations without major changes in effect. This slope influences how aggressively a clinician must manage dosing precision and monitoring intervals.

## Potency, Efficacy, and Drug Selection

Drug selection begins with matching the required efficacy to the clinical goal. For life-threatening infection, the drug must be capable of eradicating the pathogen, also suppressing it. For chronic pain management, the drug must achieve a level of analgesia compatible with acceptable quality of life. Potency then informs the dose, while efficacy informs whether the drug class is appropriate at all.

The therapeutic index quantifies the separation between effective and toxic concentrations. A narrow therapeutic index demands careful dose individualization, therapeutic drug monitoring where available, and heightened vigilance for adverse effects. A wide therapeutic index permits more standardized dosing. Species differences in drug metabolism and receptor sensitivity can shift the therapeutic index substantially, so values derived from one species cannot be assumed for another. The MSD Veterinary Manual provides species-specific pharmacologic guidance that accounts for these differences in clinical application.

## Pharmacodynamic Indices for Antimicrobials

Antimicrobial pharmacodynamics has advanced further than most other therapeutic areas in veterinary medicine. The relationship between drug exposure and bacterial eradication has been characterized for major drug classes, and these relationships now inform dosing interval design. Three primary pharmacodynamic indices describe antimicrobial exposure: the percentage of the dosing interval during which the free drug concentration exceeds the minimum inhibitory concentration (T>MIC), the ratio of the area under the concentration-time curve to the MIC (AUC/MIC), and the ratio of the peak concentration to the MIC (Cmax/MIC).

Beta-lactams demonstrate time-dependent killing. Their bactericidal activity saturates at concentrations modestly above the MIC, and further concentration increases do not accelerate killing. The critical exposure parameter is therefore the duration of time that free drug concentrations remain above the MIC. For broad-spectrum cephalosporins, maximal efficacy in animal infection models is approached when serum levels exceed the MIC for 60% to 70% of the dosing interval for Enterobacteriaceae and streptococci, and for 40% to 50% of the interval for Staphylococcus aureus, as described by Craig in his analysis of cephalosporin pharmacodynamics. This distinction matters clinically because the same drug may require different dosing intervals depending on the target pathogen.

The postantibiotic effect modifies this requirement. Beta-lactams produce prolonged postantibiotic effects against staphylococci but not against gram-negative enteric bacilli. A drug that suppresses regrowth after concentrations fall below the MIC can tolerate longer intervals below the MIC without losing efficacy. Turnidge's review of beta-lactam pharmacodynamics confirms that time above MIC correlates best with bacterial eradication in animal models, with human studies increasingly supporting the same conclusion. Trough serum inhibitory titers have correlated better with cure than peak titers in investigations of osteomyelitis and endocarditis, and clinical efficacy declines as the MIC of the infecting pathogen rises.

## Concentration-Dependent and Co-Dependent Killing

Aminoglycosides and fluoroquinolones exhibit concentration-dependent killing. Higher drug concentrations produce more rapid and more extensive bacterial killing, and the ratio of peak concentration to MIC becomes the primary predictor of efficacy. These drugs also produce prolonged postantibiotic effects against many gram-negative pathogens, which permits extended dosing intervals without sacrificing efficacy. The clinical consequence is that large, infrequent doses are often more effective and less toxic than frequent small doses, provided the peak concentration target is met.

Some drug classes display co-dependent pharmacodynamics, where both the AUC/MIC ratio and the time above a threshold concentration contribute to efficacy. Fluoroquinolones are often described in this category, with the AUC/MIC ratio serving as the dominant index. The practical implication is that both the dose and the dosing interval must be optimized together, and that suboptimal exposure cannot be fully compensated by increasing dose alone.

## Integration with Pharmacokinetics

Pharmacodynamic indices become clinically useful only when linked to the pharmacokinetic profile of the drug in the target species. The same pharmacodynamic target can be achieved with different dosing strategies depending on drug half-life, volume of distribution, and protein binding. A drug with a long half-life may meet a T>MIC target with once-daily dosing, while a short half-life drug requires continuous infusion or frequent administration.

The relationship between pharmacokinetics and pharmacodynamics in determining dosage regimens was articulated by Craig for the broad-spectrum cephalosporins, where the time above MIC goals can be met with 12-hour dosing intervals in infected or elderly patients based on MIC90 values of 0.5 microgram/mL for enteric bacilli and 4 micrograms/mL for S. aureus. This integration of pathogen susceptibility data, drug disposition, and pharmacodynamic target defines rational dosing.

Therapeutic drug monitoring applies this integration directly. For tuberculosis therapy in human medicine, plasma concentration measurements guide dosing decisions, with a 2-hour post-dose sample approximating the peak concentration for most drugs and a 6-hour sample distinguishing delayed absorption from malabsorption. Veterinary application of therapeutic drug monitoring remains limited by assay availability and cost, but the same principles apply when monitoring is feasible.

## Applying Pharmacodynamic Principles in Clinical Dosing Decisions

### Selecting a Dosing Strategy Based on the PD Target

The first decision point in clinical dosing is identifying which pharmacodynamic index governs the drug class being used. For beta-lactams, the duration of time that serum concentrations exceed the minimum inhibitory concentration (MIC), expressed as a percentage of the dosing interval, is the parameter that correlates best with bacterial eradication in animal models and human studies [Turnidge's review of beta-lactam pharmacodynamics](https://pubmed.ncbi.nlm.nih.gov/9675443/). Maximal efficacy for cephalosporins is approached when serum levels remain above the MIC for 60% to 70% of the dosing interval for Enterobacteriaceae and streptococci, and for 40% to 50% of the interval for Staphylococcus aureus [Craig's analysis of cephalosporin dosing regimens](https://pubmed.ncbi.nlm.nih.gov/7587056/).

For concentration-dependent agents such as aminoglycosides and fluoroquinolones, the ratio of peak concentration to MIC or the ratio of area under the curve to MIC governs efficacy. The practical consequence is that these drugs should be given as larger, less frequent doses instead of divided into multiple small doses. For time-dependent agents, the dosing interval itself, not the size of each individual dose, is the primary lever for improving efficacy.

The correct choice changes with the pathogen. A beta-lactam that provides 50% time above MIC may be adequate for staphylococcal infection but marginal for enteric bacilli. When the infecting organizm is unknown or when MIC data are unavailable, the clinician should dose against the most demanding likely pathogen. When MIC data are available, the dosing interval should be checked against the expected time above MIC for that specific value.

### The Therapeutic Index as a Dose-Limiting Constraint

Potency and efficacy describe what a drug can do. The therapeutic index describes what a drug can do safely. A drug with excellent efficacy but a narrow therapeutic index requires a different dosing strategy than one with a wide margin.

Ketamine illustrates this tension. The S(+) enantiomer is approximately four times more potent as an anesthetic and analgesic than the R(-) enantiomer and about two times more effective than the racemic mixture [review of ketamine pharmacokinetics and pharmacodynamics](https://pubmed.ncbi.nlm.nih.gov/27028535/). A clinician switching from racemic ketamine to S-ketamine must reduce the dose accordingly. The hemodynamic stability of ketamine, mediated by central sympathetic stimulation without respiratory depression, makes it useful in patients where other anesthetics carry greater risk. But the same potency that makes S-ketamine attractive also narrows the margin for dosing error.

Liposomal amphotericin B presents a different therapeutic index problem. The lipid formulation has a significantly improved toxicity profile compared with amphotericin B deoxycholate while retaining the antifungal effect of the active agent [review of liposomal amphotericin B](https://pubmed.ncbi.nlm.nih.gov/26818726/). The long terminal half-life and tissue retention of the liposomal formulation suggest that single or intermittent dosing regimens may be feasible, but significant gaps remain in understanding its pharmacokinetics and pharmacodynamics in neonates, children, pregnant women, and obese patients. In these populations, the clinician should default to more frequent monitoring and more conservative dose escalation.

### Monitoring Parameters and What Each One Detects

Therapeutic drug monitoring converts pharmacodynamic theory into individual patient management. For tuberculosis treatment, monitoring serves a specific purpose: identifying patients who are slow to respond and shortening the time to treatment completion [update on therapeutic drug monitoring in tuberculosis](https://pubmed.ncbi.nlm.nih.gov/24846578/). A 2-hour post-dose sample approximates the peak serum concentration for most TB drugs. Adding a 6-hour sample distinguishes delayed absorption from malabsorption. Sample handling matters. Isoniazid and ethionamide are not stable in serum at room temperature, so prompt centrifugation and freezing are required. Rifampicin remains stable for more than 6 hours under the same conditions.

The monitoring parameter should match the PD index of the drug. For time-dependent drugs, trough concentrations are more informative than peaks. For concentration-dependent drugs, peak concentrations or area under the curve estimates are the relevant targets. For drugs with a narrow therapeutic index, both peak and trough may need to be measured.

| Drug Class | PD Index | Primary Monitoring Parameter | Clinical Decision Point |
|---|---|---|---|
| Beta-lactams | Time above MIC | Trough concentration | Shorten interval if trough falls below MIC before next dose |
| Aminoglycosides | Peak/MIC ratio | Peak concentration 30-60 min after dose | Increase dose if peak/MIC ratio is inadequate |
| Fluoroquinolones | AUC/MIC ratio | Area under the curve estimate | Adjust dose or interval based on estimated exposure |
| Glycopeptides | AUC/MIC ratio | Trough concentration as surrogate | Adjust dose to maintain target trough range |
| Azoles | AUC/MIC ratio | Trough concentration | Adjust dose for absorption or drug interactions |
| Aminoglycosides (once daily) | Peak/MIC ratio | Peak concentration | Extend interval if trough remains detectable |

### Species and Production System Modifications

The same pharmacodynamic principle does not translate directly across species. Differences in protein binding, metabolic rate, and elimination half-life change the relationship between dose and exposure. A dosing interval that achieves 70% time above MIC in one species may achieve only 30% in another with faster clearance.

In food animals, the choice of drug and dosing strategy is constrained by withdrawal periods and by regulatory frameworks that differ between jurisdictions. The World Organization for Animal Health provides international standards for animal health and trade-related disease control [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/), and the FDA Center for Veterinary Medicine regulates approved animal drugs and labeling in the United States [FDA animal drug information](https://www.fda.gov/animal-veterinary). Extralabel use is permitted under specific conditions but requires careful attention to withdrawal interval estimation. The AVMA provides professional guidance on judicious antimicrobial use and stewardship principles [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance).

Patient status changes the correct choice. In a patient with renal impairment, a drug cleared renally will accumulate, and the dosing interval should be extended instead of the dose reduced for time-dependent drugs. For concentration-dependent drugs, reducing the dose while maintaining the interval preserves the peak/MIC ratio. In obese patients, the volume of distribution for lipophilic drugs increases, and dosing based on actual body weight may produce excessive exposure.

### Documenting the PD Rationale

The medical record should state the PD target, the basis for the chosen dosing interval, and the monitoring plan. For antimicrobials, record the suspected or confirmed pathogen, the MIC if available, the PD index for the drug class, and how the chosen dose and interval achieve the target. For drugs with a narrow therapeutic index, record the monitoring schedule and the threshold values that would trigger a dose change.

When MIC data are unavailable, document the assumption made about the likely MIC and the rationale for that assumption. When the patient fails to respond, the PD analysis should be revisited before changing drugs. A drug that is potent in vitro may fail in vivo because the dosing interval does not achieve the required exposure. Increasing the dose of a time-dependent drug given too infrequently will not fix the problem. Shortening the interval or switching to a continuous infusion addresses the actual failure mode.

The same logic applies to non-antimicrobial drugs. For ketamine, the analgesic and anesthetic effects are concentration-related, and the dosing strategy should account for the route of administration. Oral bioavailability is poor because of extensive first-pass metabolism, while nasal administration produces rapid peak concentrations with relatively high bioavailability [review of ketamine clinical pharmacokinetics](https://pubmed.ncbi.nlm.nih.gov/27028535/). A dose that works by one route cannot be assumed to work by another.

## Recognized Complications and Failure Modes

The most common clinical failure in pharmacodynamic application is not drug inefficacy but target misidentification. When the clinician selects a dosing interval based on the wrong PD index, even a correctly calculated dose will underperform. For beta-lactams, the time above MIC governs bacterial eradication, and this relationship holds across in vitro systems, animal infection models, and human studies. A clinician who treats a beta-lactam as though it were concentration-dependent, and therefore extends the interval to exploit a high peak, will leave the pathogen exposed for a substantial portion of the dosing cycle. The early warning sign is clinical deterioration after an initial response, or a failure to defervesce within the expected window.

A second failure mode is the uncritical use of MIC values without considering the site of infection. The MIC is determined in broth under standardized conditions and does not reflect drug penetration into sequestered foci, biofilm, or intracellular compartments. For liposomal amphotericin B, the relationship between measured plasma concentrations and clinical effect is poorly defined, and tissue retention instead of circulating drug may drive efficacy. A clinician who titrates therapy against plasma drug concentrations alone may misjudge the true pharmacodynamic exposure at the effect site.

A third failure mode is the assumption that a single PD target applies across pathogens and host states. Craig's work with broad-spectrum cephalosporins demonstrated that the time above MIC required for maximal efficacy differs by organizm: 60% to 70% of the dosing interval for Enterobacteriaceae and streptococci, but 40% to 50% for Staphylococcus aureus. Applying a uniform target across all bacterial species will either overtreat or undertreat depending on the pathogen.

| Observation | Likely Cause | Discriminating Check |
| --- | --- | --- |
| Clinical response despite MIC above the susceptibility breakpoint | Concentration-dependent killing at the infection site, or host immune contribution | Recheck MIC with a validated method, assess infection site penetration |
| Slow response to a beta-lactam with documented susceptibility | Time above MIC target not met for the specific pathogen | Calculate the percentage of the dosing interval above the MIC for the isolated organizm |
| Toxicity at standard doses | Accumulation due to organ dysfunction, or a narrow therapeutic index | Measure trough concentrations, review hepatic and renal function |
| Apparent resistance emerging during therapy | Suboptimal exposure selecting for resistant subpopulations | Repeat culture and susceptibility testing, review the PD index used for dosing |

## Common Errors and Corrective Actions

Less experienced clinicians frequently confuse potency with efficacy when selecting between two drugs in the same class. A drug with a lower MIC is more potent, but potency does not predict the maximum achievable effect. The choice between two beta-lactams should rest on the time above MIC achievable with the dosing schedule, not on which drug has the lower MIC in vitro.

A second recurring error is the failure to distinguish between a postantibiotic effect and time-dependent killing. Beta-lactams produce variable postantibiotic effects, and for most gram-negative pathogens the effect is short or absent. A clinician who assumes a prolonged postantibiotic effect and extends the dosing interval accordingly will create a gap in coverage. The corrective action is to verify the postantibiotic effect for the specific drug-pathogen combination before extending intervals.

A third error is the use of a single time point to assess drug exposure without considering the shape of the concentration-time curve. For tuberculosis therapy, a 2-hour post-dose sample approximates the peak concentration for most drugs, and adding a 6-hour sample distinguishes delayed absorption from malabsorption. A clinician who samples only at 2 hours may misinterpret a delayed peak as malabsorption and inappropriately increase the dose.

## Limitations of the Evidence and Areas of Expert Disagreement

The evidence base for pharmacodynamic targets is strongest for antimicrobials in experimental infection models and human studies, and weaker for other drug classes and for veterinary species specifically. The time above MIC targets for cephalosporins were derived largely from animal infection models and have been corroborated in human studies, but direct veterinary clinical validation is limited. Extrapolation across species requires caution because protein binding, metabolic rate, and immune competence differ.

For antifungal therapy, the pharmacodynamic relationships are less well established. Liposomal amphotericin B has a long terminal half-life and significant tissue retention, which suggests that intermittent dosing may be feasible, but the optimal PD index remains uncertain. Expert opinion differs on whether plasma concentration monitoring is clinically useful for this drug class.

For ketamine, the pharmacodynamic picture is complicated by the presence of two enantiomers with different potencies. The S-enantiomer is approximately four times more potent than the R-enantiomer as an anesthetic and analgesic. Clinicians who use racemic mixtures or who switch between formulations without adjusting for enantiomeric composition may produce inconsistent effects.

## Referral, Consultation, and Reporting

Referral to a specialist is warranted when the clinician cannot achieve the PD target with available formulations, when the infection site is inaccessible to standard dosing, or when toxicity limits dose escalation. A veterinary clinical pharmacologist or a specialist in the relevant discipline can assist with alternative dosing strategies, therapeutic drug monitoring protocols, or the use of combination therapy.

Laboratory involvement is indicated when MIC testing is not routinely performed, when the laboratory uses methods that do not align with the PD framework, or when susceptibility results are inconsistent with the clinical response. The laboratory should be consulted about the appropriate testing method and about the interpretation of results for the specific pathogen and drug.

Regulatory reporting is required when an adverse drug event occurs, when an extralabel use is associated with a suspected toxicity, or when a product failure is suspected. The FDA Center for Veterinary Medicine provides channels for reporting adverse events and for accessing information on approved animal drugs and extralabel use policy. Professional guidance on judicious antimicrobial use and stewardship principles is available through the AVMA. International standards for animal health and trade-related disease control are published by the World Organization for Animal Health.

## Frequently Asked Questions

### How Do I Choose a Dosing Interval When the Ideal Pharmacodynamic Target Cannot Be Met?

When the optimal PD target is unattainable, prioritize the index that best predicts clinical efficacy for the drug class in question. For time-dependent agents such as beta-lactams, extend the dosing interval only if the duration of time above the MIC remains adequate for the pathogen and infection site. Craig's work on broad-spectrum cephalosporins demonstrated that serum levels above the MIC for 60% to 70% of the interval sufficed for Enterobacteriaceae and streptococci, while 40% to 50% sufficed for Staphylococcus aureus. If these targets cannot be reached with a practical interval, consider a continuous infusion, combination therapy, or an alternative drug class with a more forgiving PD profile. Document the compromise and reassess the patient's response earlier than usual.

### What Should I Do When Therapeutic Drug Monitoring Is Unavailable?

Therapeutic drug monitoring is a standard technique for using plasma concentrations to guide dosing decisions, but it is not universally accessible. When TDM is unavailable, use published population pharmacokinetic values and MIC data from culture and susceptibility testing to estimate whether the PD target is likely met. For time-dependent drugs, calculate the expected time above MIC using published clearance and volume estimates for the species. For concentration-dependent drugs, estimate the peak concentration relative to the MIC using standard dose ranges from a current formulary. Choose the most conservative estimate when uncertainty exists. If the patient fails to respond, consider referral to a facility with TDM capacity instead of escalating doses blindly.

### How Do Pharmacodynamic Principles Apply Differently in Exotic or Food Animal Species?

PD targets derived from mammalian models generally transfer across species, but the pharmacokinetic component does not. Metabolic rate, protein binding, and elimination pathways differ substantially between ruminants, camelids, birds, and reptiles. For food animals, withdrawal intervals must be established from label data or legal extralabel reference sources, not extrapolated from PD calculations. Regulatory oversight of antimicrobial use in food animals varies by region, and practitioners should consult the [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary) and [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) for applicable requirements. In exotic species, published PD data are often absent, so use the most closely related domestic species as a starting point and monitor response carefully.

### How Should I Explain a Pharmacodynamic-Based Dosing Change to a Client?

Frame the explanation around why the dose or interval is changing, not the mathematics. State that the goal is to keep drug concentrations above the level needed to suppress the infection for a sufficient portion of the day, or to achieve a high enough peak concentration to kill the organizm efficiently. Use an analogy such as maintaining a room at a set temperature instead of briefly overheating it. Explain that the change may mean more frequent dosing, which can be inconvenient, but that it improves the chance of cure and may reduce the risk of resistance. Provide a written schedule and clarify what to do if a dose is missed. Reassure the client that the adjustment is based on established pharmacodynamic principles, not on a perceived failure of the previous regimen.

### What Documentation Should I Maintain for Pharmacodynamic-Based Dosing Decisions?

Record the PD target chosen, the MIC value used, the estimated pharmacokinetic parameters, and the rationale for the dose and interval selected. Note the source of the susceptibility data and any assumptions made when population values were substituted for individual patient data. If the chosen regimen deviates from label directions, document the extralabel basis and the monitoring plan. For food animals, record the withdrawal interval determination and the reference used. This documentation supports continuity of care, defends professional decisions, and satisfies stewardship expectations. The [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) provide guidance on judicious use documentation that applies across practice settings.

### How Do Cost Constraints Affect Pharmacodynamic-Based Drug Selection?

Cost is a legitimate clinical variable, but it should be weighed against the probability of treatment failure. A cheaper drug given at a suboptimal dose or interval may require a second course, incurring greater total expense and promoting resistance. When budget limits the options, select the drug with the most forgiving PD profile for the suspected pathogen. For time-dependent drugs, choose an agent with a long half-life or low MIC against the target organizm. For concentration-dependent drugs, select one with a wide therapeutic index so that a higher dose remains safe. Discuss the trade-off openly with the owner, and document that the chosen regimen was selected with cost as a factor while still meeting the minimum PD target where feasible.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.](https://pubmed.ncbi.nlm.nih.gov/7587056/). 1995.
- [Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.](https://pubmed.ncbi.nlm.nih.gov/23371303/). 2013.
- [Therapeutic drug monitoring in the treatment of tuberculosis: an update.](https://pubmed.ncbi.nlm.nih.gov/24846578/). 2014.
- [Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.](https://pubmed.ncbi.nlm.nih.gov/27028535/). 2016.
- [The pharmacodynamics of beta-lactams.](https://pubmed.ncbi.nlm.nih.gov/9675443/). 1998.
- [Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.](https://pubmed.ncbi.nlm.nih.gov/26818726/). 2016.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Antimicrobial Stewardship in Food Animals: Principles and Practical Application](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-food-animals-principles-practical-application)
- [Dose Adjustment in Hepatic Disease: Pharmacokinetic Principles for Veterinary Patients](/knowledge/veterinary-medicine/clinical-pharmacology/dose-adjustment-hepatic-disease-veterinary)
- [Pharmacodynamic Drug Interactions in Veterinary Medicine: Additive, Synergistic, and Antagonistic Effects](/knowledge/veterinary-medicine/clinical-pharmacology/pharmacodynamic-drug-interactions-veterinary-medicine)
- [Pharmacokinetic Principles for Clinical Dosing Decisions](/knowledge/veterinary-medicine/clinical-pharmacology/pharmacokinetic-principles-for-clinical-dosing-decisions)
- [Corticosteroid Therapy in Feline Diseases: Special Considerations](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-feline-diseases-special-considerations)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.